title: [Neuroprotective effect of curcumin to Aβ of double transgenic mice with Alzheimer's disease].
abstract: OBJECTIVE
  To observe the changes in Aβ40, Aβ42 and ADDLs in brains of 3 month-old APPswe/PS1dE9 double transgenic mice after six-month intervention with curcumin, in order to discuss the neuroprotective effect of curcumin.
  
  
  METHODS
  APPswe/PS1dE9dtg mice were randomly divided into the model group, the Rosiglitazone group (10 mg x kg(-1) x d(-1)) and curcumin high (400 mg x kg9-1) x d(-1)), medium (200 mg x kg(-1) x d(-1)) and low (100 mg x kg(-1) x d(-1)) dosage groups, with C57/BL6J mice of the same age and the same background in the normal control group. After 6 months, the immunohistochemical staining (IHC) and the Western blot method were used to observe the changes in positive cell of Aβ40, Aβ42 and ADDLs in hippocampal CA1 area, their distribution and protein expressions.
  
  
  RESULTS
  Both of the immunohistochemical staining and the Western blot method showed more positive cell of Aβ40, Aβ42 and ADDLs in hippocampal CA1 area and higher protein expressions in the model group than the normal group (P < 0.01). IHC showed a lower result in the Rosiglitazone group than the model group (P < 0.05), while Western blot showed a much lower result (P < 0.01). The number of Aβ40, Aβ42 and ADDLs positive cells and the protein expressions decreased in the curcumin high group, the medium group showed a significant decrease (P < 0.01), and the low dose group also showed reductions in the protein expressions of Aβ40 and Aβ42.
  
  
  CONCLUSIONS
  The six-month intervention with curcumin can significantly reduce the expressions of hippocampal Aβ40, Aβ42 and ADDLs in brains of APPswe/PS1dE9 double transgenic mice. Whether curcumin can impact Aβ cascade reaction by down-regulating expressions of Aβ40, Aβ42 and ADDLs and show the neuroprotective effect needs further studies.
authors.forename: Hui-Li
authors.initials: HL
authors.lastname: Feng
authors.forename: Hui
authors.initials: H
authors.lastname: Fan
authors.forename: Hui-Zi
authors.initials: HZ
authors.lastname: Dang
authors.forename: Xiao-Pei
authors.initials: XP
authors.lastname: Chen
authors.forename: Ying
authors.initials: Y
authors.lastname: Ren
authors.forename: Jin-Duo
authors.initials: JD
authors.lastname: Yang
authors.forename: Peng-Wen
authors.initials: PW
authors.lastname: Wang
mesh_terms: D000544:Alzheimer Disease / Q000188:drug therapy* / Q000235:genetics / Q000378:metabolism; D016229:Amyloid beta-Peptides / Q000235:genetics / Q000378:metabolism; D000818:Animals; D001921:Brain / Q000187:drug effects / Q000378:metabolism; D003474:Curcumin / Q000008:administration & dosage*; D004195:Disease Models, Animal; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D051379:Mice; D008810:Mice, Inbred C57BL; D008822:Mice, Transgenic; D018696:Neuroprotective Agents / Q000008:administration & dosage*; D010936:Plant Extracts / Q000008:administration & dosage*
chemical_list: D016229:Amyloid beta-Peptides; D018696:Neuroprotective Agents; D010936:Plant Extracts; D003474:Curcumin